NO20082767L - Kimaere og humaniserte anti-humane IL-13 antistoffer - Google Patents

Kimaere og humaniserte anti-humane IL-13 antistoffer

Info

Publication number
NO20082767L
NO20082767L NO20082767A NO20082767A NO20082767L NO 20082767 L NO20082767 L NO 20082767L NO 20082767 A NO20082767 A NO 20082767A NO 20082767 A NO20082767 A NO 20082767A NO 20082767 L NO20082767 L NO 20082767L
Authority
NO
Norway
Prior art keywords
antibodies
human
chimeric
diseases
humanized anti
Prior art date
Application number
NO20082767A
Other languages
English (en)
Norwegian (no)
Inventor
Jonathan Henry Ellis
Martin John Cassidy
Trevor Anthony Kenneth Wattam
Ashman Claire
Jane Elizabeth Clarkson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082767(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082767L publication Critical patent/NO20082767L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20082767A 2006-01-11 2008-06-16 Kimaere og humaniserte anti-humane IL-13 antistoffer NO20082767L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins
PCT/EP2007/050219 WO2007080174A2 (fr) 2006-01-11 2007-01-10 Immunoglobulines

Publications (1)

Publication Number Publication Date
NO20082767L true NO20082767L (no) 2008-10-06

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082767A NO20082767L (no) 2006-01-11 2008-06-16 Kimaere og humaniserte anti-humane IL-13 antistoffer

Country Status (18)

Country Link
EP (1) EP1976881A2 (fr)
JP (1) JP2009523154A (fr)
KR (1) KR20080113201A (fr)
CN (1) CN101370829A (fr)
AR (1) AR058955A1 (fr)
AU (1) AU2007204372A1 (fr)
BR (1) BRPI0706481A2 (fr)
CA (1) CA2635972A1 (fr)
CR (1) CR10161A (fr)
EA (1) EA200801520A1 (fr)
GB (1) GB0600488D0 (fr)
IL (1) IL192207A0 (fr)
MA (1) MA30156B1 (fr)
NO (1) NO20082767L (fr)
PE (1) PE20081185A1 (fr)
TW (1) TW200736274A (fr)
WO (1) WO2007080174A2 (fr)
ZA (1) ZA200805526B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957530A2 (fr) 2005-10-21 2008-08-20 Novartis AG Anticorps humains contre l'il-13 et ses utilisations therapeutiques
EP2027157B1 (fr) 2006-05-25 2014-08-06 Glaxo Group Limited Anticorps anti-interleukine-18, modifies et humanises
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
WO2010060486A1 (fr) * 2008-11-26 2010-06-03 Glaxo Group Limited Ligands qui se lient à il-13
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
SG176203A1 (en) 2009-05-28 2011-12-29 Glaxo Group Ltd Il-13 binding protein
MX341136B (es) 2009-10-20 2016-08-09 Abbvie Inc Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a.
HUE034005T2 (en) * 2010-10-15 2018-01-29 Medimmune Ltd Therapies for improving lung function
WO2012083132A2 (fr) 2010-12-16 2012-06-21 Genentech, Inc. Diagnostic et traitements associés à l'inhibition de th2
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
WO2015061441A1 (fr) 2013-10-23 2015-04-30 Genentech, Inc. Méthodes de diagnostic et de traitement de troubles éosinophiliques
BR112016018980A2 (pt) 2014-02-21 2017-10-10 Genentech Inc método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
AU2015246037B2 (en) 2014-04-11 2018-04-12 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2017162604A1 (fr) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement de lentigos séniles
JPWO2018135653A1 (ja) * 2017-01-23 2020-01-09 学校法人 東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
CN109776677B (zh) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 一种人源化抗il-13抗体及其制备方法和应用
CN107909501B (zh) * 2017-12-05 2020-12-01 创新先进技术有限公司 气味与行为的关联方法、气味社交方法及装置
WO2019157358A1 (fr) 2018-02-09 2019-08-15 Genentech, Inc. Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
WO2020191293A1 (fr) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anticorps anti-adam12 et récepteurs antigéniques chimériques ainsi que compositions et méthodes les comprenant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019975A2 (fr) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
WO2004096849A2 (fr) * 2003-04-25 2004-11-11 University Of Manitoba Vaccins peptidiques a base de cytokines/chimiokines contre l'allergie
SI1703893T1 (sl) * 2003-12-23 2012-07-31 Genentech Inc Nova protitelesa proti il in uporaba le teh
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
CR10161A (es) 2008-11-26
ZA200805526B (en) 2009-10-28
GB0600488D0 (en) 2006-02-22
EA200801520A1 (ru) 2009-02-27
WO2007080174A2 (fr) 2007-07-19
AR058955A1 (es) 2008-03-05
PE20081185A1 (es) 2008-10-07
WO2007080174A3 (fr) 2007-12-06
TW200736274A (en) 2007-10-01
AU2007204372A1 (en) 2007-07-19
BRPI0706481A2 (pt) 2011-03-29
MA30156B1 (fr) 2009-01-02
KR20080113201A (ko) 2008-12-29
CN101370829A (zh) 2009-02-18
IL192207A0 (en) 2008-12-29
JP2009523154A (ja) 2009-06-18
CA2635972A1 (fr) 2007-07-19
EP1976881A2 (fr) 2008-10-08

Similar Documents

Publication Publication Date Title
NO20082767L (no) Kimaere og humaniserte anti-humane IL-13 antistoffer
NO20070189L (no) Immunoglobuliner
HRP20190762T1 (hr) Protutijela koja se vežu prvenstveno na izvanstaničnu domenu 4 ljudskog csf1r i njihova uporaba
EA201590631A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
NO20091411L (no) Interleukin-13-bindende proteiner
JO2576B1 (en) Antibodies
MX2009010765A (es) Anticuerpos anti-ige.
PH12013501033A1 (en) Antibodies that bind il-4 and\or il-13 and their uses
WO2010021874A3 (fr) Anticorps anti-il-13 modifiés, compositions, procédés et utilisations
WO2007127317A3 (fr) Anticorps c-kit humanisé
NO20081946L (no) Interleukin-13 antistoffsammensetning
WO2010038155A3 (fr) Anticorps contre il-25
MX2022008255A (es) Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica.
MY200912A (en) Biopharmaceutical Compositions and Related Methods
WO2009090656A3 (fr) Polythérapie à base de bêta-glycolipides et d'anticorps pour le traitement de troubles de nature immunitaire
MY163133A (en) Humanized il-25 antibodies
WO2008042941A3 (fr) Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse
JP2016047843A5 (fr)
UA100531C2 (ru) Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp)
TH83335B (th) อิมมูโนโกลบูลิน
TH83335A (th) อิมมูโนโกลบูลิน
TH97785A (th) อิมมูโนโกลบูลิน
TW200610768A (en) IL-13 binding antibodies
BRPI0716611A2 (pt) anticorpo monoclonal quimérico, ácido nucléico isolado, célula isolada, composição farmacêutica, e, método para tratar uma doença ou distúrbio

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application